Australian Medtech Manufacturing Alliance
To grow opportunities for medtech manufacturers to sell to health services, a new initiative, the Australian Medtech Manufacturing Alliance (AMMA), is forming to create a connected programme, led in Victoria and building on the work of the Australian…
Platform Expansion: Gastric Cancer Diagnostic Test Update
Posted: 25 September 2024 Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (“Rhythm” or the “Company”) is pleased to provide an update on its cancer diagnostics technology platform expansion program in gastric cancer. Rhythm has…
Cartherics enters agreements with UniQuest, The University of Queensland and The University of Sydney for advancing innovative cardiac cellular therapy
Posted: 25 September 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered into a Technology Licence Agreement (TLA) with The University…
Study sheds light on how antibodies protect children from cerebral malaria
Posted: 25 September 2024 In a first-of-its-kind study, an international team of researchers has discovered how specific antibodies in young children protect against cerebral malaria, a life-threatening condition caused by the Plasmodium falciparum parasite, paving the way for…
One-two punch treatment delivers blood cancer knockout
Posted: 25 September 2024 A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancer. A new study by WEHI…
Researchers ‘turbocharge’ vaccine delivery by jolting ‘bystander’ immune cells into action in animal models
Posted: 25 September 2024 Monash University researchers have developed a new technique to boost the effectiveness of both traditional and mRNA-based vaccines in animal models. Published in Immunity, the study found that adding low doses of vaccine-specific antibody to…
Telix to acquire RLS to expand North American manufacturing and distribution platform
Posted: 25 September 2024 Telix and RLS (USA) Inc., America’s only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent company, RLS Group Ltd. The…
PAT-DX1 GMP specification testing update
Posted: 23 September 2024 Patrys Limited, a therapeutic antibody development company, provides the following update regarding the recently completed GMP manufacturing run of PAT-DX1. Patrys’ Contract Development Manufacturing Organisation (CDMO) has advised the Company that the Quality Assurance…
Tumour response in sixth patient triggers additional recruitment in pancreatic cancer trial
Posted: 23 September 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial) has achieved…
Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology
Posted: 23 September 2024 Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models…
FDA Fast Track Designation For Narmafotnib in Advanced Pancreatic Cancer
Posted: 23 September 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib,…
Major $21m Colonial Foundation philanthropic investment to bring future science into disease diagnosis
Posted: 23 September 2024 An outstanding $21 million philanthropic investment will establish a pioneering research centre to advance precision diagnosis for diseases that affect millions of Australians. The Colonial Foundation Diagnostics Centre will use cutting-edge ‘spatial biology’ technologies…
